_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
The platform is being introduced to expand access to treatments for people living with chronic conditions
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Subscribe To Our Newsletter & Stay Updated
